论文部分内容阅读
RNAi与高内涵筛选联合应用,可作为药物研发过程中大规模靶标筛选、候选靶标确证的重要方法,还可用于化合物的筛选及作用机制研究;在HCS技术平台上平行进行功能基因组学和化学遗传学研究可同时筛选靶标和先导化合物。RNAi与HCS联合应用在药物研发中显示显著优势的同时,也常被数据的捕获、管理、分析等技术挑战所限制,尤其是海量图像的自动分析,如细胞分界及细胞表型识别分类等。
RNAi combined with high content screening can be used as an important method for large-scale target screening and candidate target confirmation during drug discovery and development. It can also be used for the screening of compounds and their mechanism of action. Parallel functional genomics and chemical genetic Studies can screen targets and lead compounds simultaneously. The combination of RNAi and HCS shows significant advantages in drug development and is often limited by technical challenges such as capture, management and analysis of data, especially in automatic analysis of massive images such as cell demarcation and cell phenotype recognition.